{"id":5524,"date":"2022-09-19T10:00:00","date_gmt":"2022-09-19T08:00:00","guid":{"rendered":"https:\/\/staybletherapeutics.com\/sv\/cision-feed\/kalqyl-publicerar-analys-av-stayble-therapeutics\/"},"modified":"2022-09-19T10:00:00","modified_gmt":"2022-09-19T08:00:00","slug":"kalqyl-publicerar-analys-av-stayble-therapeutics","status":"publish","type":"cision-feed","link":"https:\/\/staybletherapeutics.com\/sv\/cision-feed\/kalqyl-publicerar-analys-av-stayble-therapeutics\/","title":{"rendered":"Kalqyl publicerar analys av Stayble Therapeutics"},"content":{"rendered":"<p style=\"margin-bottom:0pt;margin-top:12px\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">I syfte \u00f6ka f\u00f6rst\u00e5elsen om Staybles verksamhet och var Bolaget befinner sig har Kalqyl f\u00e5tt i uppdrag att g\u00f6ra en analys av Stayble. F\u00f6rutom att presentera kommande triggers, inneh\u00e5ller analysen en oberoende granskning av Staybles behandling, marknadspotentialen och den r\u00e5dande konkurrenssituationen. Kronisk diskrelaterad ryggsm\u00e4rta uppges vara en av de stora folkh\u00e4lsoproblemen och Stayble har potential att tillgodose ett stort marknadsbehov. Framgent kommer Kalqyl att bevaka Stayble l\u00f6pande och uppr\u00e4tta nya analyser. <\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">&nbsp;<\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">\u201d<\/span><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\"><em>Den viktigaste v\u00e4rdedrivaren i Stayble kommer att bli studieresultaten fr\u00e5n den p\u00e5g\u00e5ende fas 2b-studien. Detta kan ocks\u00e5 bana v\u00e4g f\u00f6r n\u00e4sta stora katalysator, som \u00e4r ett licensavtal f\u00f6r STA363. Om de positiva resultaten fr\u00e5n tidigare studier kan replikeras bed\u00f6mer vi att bolaget st\u00e5r inf\u00f6r en betydande uppv\u00e4rdering<\/em><\/span><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">,\u201d skriver analytikern fr\u00e5n Kalqyl AB.<\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">&nbsp;<\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">&nbsp;<\/span><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">L\u00e4s hela analysen h\u00e4r: <\/span><a href=\"https:\/\/kalqyl.se\/initial-take-stayble-therapeutics\" style=\"text-decoration:none\"><span style=\"color:#0000ff;font-family:arial,helvetica,sans-serif;font-size:9pt\"><u>https:\/\/kalqyl.se\/initial-take-stayble-therapeutics<\/u><\/span><\/a><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\"> <\/span><\/p>\n<p style=\"font-family:arial,helvetica,sans-serif;margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">&nbsp;<\/span><\/p>\n<h2 style=\"font-size:14pt;margin-bottom:6pt;margin-top:0pt;text-align:left\"><span style=\"color:#305584;font-family:arial,helvetica,sans-serif;font-size:9pt;font-weight:normal\">F\u00f6r mer information<\/span><\/h2>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">Andreas Gerward, VD Stayble Therapeutics AB<\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">E-post: andreas.gerward@stayble.se <\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">Telefon: +46 730 808<\/span><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">&nbsp;<\/span><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">397<\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">&nbsp;<\/span><\/p>\n<h2 style=\"font-size:14pt;margin-bottom:6pt;margin-top:0pt;text-align:left\"><span style=\"color:#305584;font-family:arial,helvetica,sans-serif;font-size:9pt;font-weight:normal\">Om Stayble Therapeutics AB<\/span><\/h2>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">Stayble \u00e4r ett kliniskt l\u00e4kemedelsbolag som utvecklar injektionsbehandlingen STA363 mot kronisk diskrelaterad ryggsm\u00e4rta. Behandlingen riktar sig till patienter som inte blir hj\u00e4lpta av sjukgymnastik och sm\u00e4rtstillande preparat. Injektionen ges vid ett tillf\u00e4lle och effekten ber\u00e4knas kvarst\u00e5 hela livet och kr\u00e4va minimal rehabilitering. Bolaget har nu fokus p\u00e5 den fortsatta kliniska utvecklingen och genomf\u00f6r just nu en klinisk fas 2b-studie. Staybles vision \u00e4r att utveckla STA363 som ny standardbehandling f\u00f6r patienter som lider av kronisk diskrelaterad ryggsm\u00e4rta. <\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">&nbsp;<\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">Bolagets Certified Adviser \u00e4r Svensk Kapitalmarknadsgranskning AB som n\u00e5s p\u00e5 telefonnummer +46 11 32 30 732 eller e-post <\/span><a href=\"mailto:ca@skmg.se\" style=\"text-decoration:none\"><span style=\"color:#0000ff;font-family:arial,helvetica,sans-serif;font-size:9pt\"><u>ca@skmg.se<\/u><\/span><\/a><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\"> <\/span><\/p>\n<p style=\"margin-bottom:0pt;margin-top:0pt\"><span style=\"font-family:arial,helvetica,sans-serif;font-size:9pt\">&nbsp;<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Stayble Therapeutics AB (\u201dStayble\u201d eller \u201dBolaget\u201d) har nyligen ing\u00e5tt i ett avtal med analysbolaget Kalqyl AB (\u201cKalqyl\u201d) som nu har publicerat den f\u00f6rsta analysen av Stayble.<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed\/5524"}],"collection":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed"}],"about":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/types\/cision-feed"}],"replies":[{"embeddable":true,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/comments?post=5524"}],"version-history":[{"count":0,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed\/5524\/revisions"}],"wp:attachment":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/media?parent=5524"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}